Annalaura Mastrangelo

Annalaura Mastrangelo

Auto-generated profile, based on publicly available information

Annalaura Mastrangelo

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
SWStefanie K. Wculek
Stefanie K. Wculek
GDGillian Dunphy
Gillian Dunphy
IHIgnacio Heras-Murillo
Ignacio Heras-Murillo
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
David SanchoDavid Sancho
David Sancho
Cellular metabolism orchestrates the intricate use of tissue fuels for catabolism and anabolism to generate cellular energy and structural components. The emerging field of immunometabolism highlights the importance of cellular metabolism for the maintenance and activities of immune cells. Macrophages are embryo- or adult bone marrow-derived leukocytes that are key for healthy tissue homeostasis but can also contribute to pathologies such as metabolic syndrome, atherosclerosis, fibrosis or cancer. Macrophage metabolism has largely been studied in vitro. However, different organs contain diverse macrophage populations that specialize in distinct and often tissue-specific functions. This context specificity creates diverging metabolic challenges for tissue macrophage populations to fulfill their homeostatic roles in their particular microenvironment and conditions their response in pathological conditions. Here, we outline current knowledge on the metabolic requirements and adaptations of macrophages located in tissues during homeostasis and selected diseases.

1 February 2019 in Immunity
Verified
Journal Article
Open access
MMMaría Martínez-López
María Martínez-López
Salvador IborraSalvador Iborra
Salvador Iborra
RCRuth Conde-Garrosa
Ruth Conde-Garrosa
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
CDCamille Danne
Camille Danne
David SanchoDavid Sancho
David Sancho
Production of interleukin-17 (IL-17) and IL-22 by T helper 17 (Th17) cells and group 3 innate lymphoid cells (ILC3s) in response to the gut microbiota ensures maintenance of intestinal barrier function. Here, we examined the mechanisms whereby the immune system detects microbiota in the steady state. A Syk-kinase-coupled signaling pathway in dendritic cells (DCs) was critical for commensal-dependent production of IL-17 and IL-22 by CD4+ T cells. The Syk-coupled C-type lectin receptor Mincle detected mucosal-resident commensals in the Peyer's patches (PPs), triggered IL-6 and IL-23p19 expression, and thereby regulated function of intestinal Th17- and IL-17-secreting ILCs. Mice deficient in Mincle or with selective depletion of Syk in CD11c+ cells had impaired production of intestinal RegIIIγ and IgA and increased systemic translocation of gut microbiota. Consequently, Mincle deficiency led to liver inflammation and deregulated lipid metabolism. Thus, sensing of commensals by Mincle and Syk signaling in CD11c+ cells reinforces intestinal immune barrier and promotes host-microbiota mutualism, preventing systemic inflammation.

1 November 2015 in Analytica Chimica Acta
Verified
Journal Article
Closed access
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
AFAlessia Ferrarini
Alessia Ferrarini
Mª Fernanda Rey-Stolle ValcarceMª Fernanda Rey-Stolle Valcarce
Mª Fernanda Rey-Stolle Valcarce
AGAntonia García
Antonia García
CBCoral Barbas
Coral Barbas

13 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LPLaura M Pérez
Laura M Pérez
ABAurora Bernal
Aurora Bernal
BLBeatriz de Lucas
Beatriz de Lucas
NMNuria San Martin
Nuria San Martin
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
Beatriz G. GalvezBeatriz G. Galvez
Beatriz G. Galvez
Adipose stem cells (ASCs) are an appealing source of cells for therapeutic intervention; however, the environment from which ASCs are isolated may impact their usefulness. Using a range of functional assays, we have evaluated whether ASCs isolated from an obese environment are comparable to cells from non-obese adipose tissue. Results showed that ASCs isolated from obese tissue have a reduced proliferative ability and a loss of viability together with changes in telomerase activity and DNA telomere length, suggesting a decreased self-renewal capacity. Metabolic analysis demonstrated that mitochondrial content and function was impaired in obese-derived ASCs resulting in changes in favored oxidative substrates. These findings highlight the impact of obesity on adult stem properties. Hence, caution should be exercised when considering the source of ASCs for cellular therapies since their therapeutic potential may be impaired.

16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
IRIñaki Robles-Vera
Iñaki Robles-Vera
DMDiego Mañanes
Diego Mañanes
MGMiguel Galán
Miguel Galán
MFMarcos Femenía-Muiña
Marcos Femenía-Muiña
David SanchoDavid Sancho
David Sancho
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors1. However, individuals at risk for early vascular disease often remain unidentified2. Recent research has identified new molecules in the pathophysiology of atherosclerosis3, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP–I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP–I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis.

11 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ADAna Devesa
Ana Devesa
MLManuel Lobo-González
Manuel Lobo-González
JMJuan Martínez-Milla
Juan Martínez-Milla
BOBelén Oliva
Belén Oliva
IGInés García-Lunar
Inés García-Lunar
VFValentin Fuster
Valentin Fuster
Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8–53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3–L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis—characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts—and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development. [Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318]. The hypothesis of the natural history of the inflammatory process involving the atherosclerotic plaque formation. Bone marrow (BM) is implicated in the atherosclerotic process long before the appearance of acute cardiovascular events. Cardiovascular risk factors trigger BM activation, initially in the absence of systemic inflammation. As BM activation progresses, it is accompanied by an increase in haematopoietic progenitor cells and an associated increase in inflammatory markers. The next step in the process is arterial inflammation, leading to an increase in atherosclerotic burden.